Ono H, Kondo H, Gotoda T, Shirao K, Yamaguchi H, Saito D, Hosokawa K, Shimoda T, Yoshida S
Department of Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital, Tokyo, Japan.
Gut. 2001 Feb;48(2):225-9. doi: 10.1136/gut.48.2.225.
BACKGROUND: In Japan, endoscopic mucosal resection (EMR) is accepted as a treatment option for cases of early gastric cancer (EGC) where the probability of lymph node metastasis is low. The results of EMR for EGC at the National Cancer Center Hospital, Tokyo, over a 11 year period are presented. METHODS: EMR was applied to patients with early cancers up to 30 mm in diameter that were of a well or moderately histologically differentiated type, and were superficially elevated and/or depressed (types I, IIa, and IIc) but without ulceration or definite signs of submucosal invasion. The resected specimens were carefully examined by serial sections at 2 mm intervals, and if histopathology revealed submucosal invasion and/or vessel involvement or if the resection margin was not clear, surgery was recommended. RESULTS: Four hundred and seventy nine cancers in 445 patients were treated by EMR from 1987 to 1998 but submucosal invasion was found on subsequent pathological examination in 74 tumours. Sixty nine percent of intramucosal cancers (278/405) were resected with a clear margin. Of 127 cancers without "complete resection", 14 underwent an additional operation and nine were treated endoscopically; the remainder had intensive follow up. Local recurrence in the stomach occurred in 17 lesions followed conservatively, in one lesion treated endoscopically, and in five lesions with complete resection. All tumours were diagnosed by follow up endoscopy and subsequently treated by surgery. There were no gastric cancer related deaths during a median follow up period of 38 months (3-120 months). Bleeding and perforation (5%) were two major complications of EMR but there were no treatment related deaths. CONCLUSION: In our experience, EMR allows us to perform less invasive treatment without sacrificing the possibility of cure.
背景:在日本,内镜黏膜切除术(EMR)被视为早期胃癌(EGC)且淋巴结转移可能性低的病例的一种治疗选择。本文展示了东京国立癌症中心医院11年间EGC的EMR治疗结果。 方法:EMR应用于直径达30mm的早期癌症患者,这些癌症组织学类型为高分化或中分化,表面隆起和/或凹陷(I型、IIa型和IIc型),但无溃疡或明确的黏膜下浸润迹象。切除标本以2mm间隔进行连续切片仔细检查,若组织病理学显示黏膜下浸润和/或血管受累,或切除边缘不清晰,则建议手术。 结果:1987年至1998年期间,445例患者的479处癌症接受了EMR治疗,但后续病理检查发现74处肿瘤有黏膜下浸润。69%的黏膜内癌(278/405)切除边缘清晰。在127处未“完全切除”的癌症中,14例接受了额外手术,9例接受了内镜治疗;其余患者进行了密切随访。保守治疗的17处病变、内镜治疗的1处病变以及完全切除的5处病变出现了胃部局部复发。所有肿瘤均通过随访内镜诊断,随后接受手术治疗。在中位随访期38个月(3 - 120个月)内,无胃癌相关死亡病例。出血和穿孔(5%)是EMR的两大主要并发症,但无治疗相关死亡病例。 结论:根据我们的经验,EMR使我们能够在不牺牲治愈可能性的情况下进行侵入性较小的治疗。
Ann Ital Chir. 2001
Gastrointest Endosc. 2007-10
Zhonghua Wei Chang Wai Ke Za Zhi. 2018-2-25
Gastrointest Endosc. 2006-12
J Gastrointest Cancer. 2025-8-28
World J Gastrointest Endosc. 2025-3-16
J Gastrointest Cancer. 2025-3-17
Gastric Cancer. 1998-12
Endoscopy. 1999-1
Gut. 1997-8
Endoscopy. 1993-9